Rhythm Pharmaceuticals, Inc. has announced a public offering of $150 million in common stock. All securities in this offering will be offered by Rhythm, and the company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares. The offering is being conducted under a shelf registration statement on Form S-3, which became effective in March 2023. The offering's final terms, including size and conditions, will be disclosed in a prospectus supplement filed with the SEC. Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities are serving as joint book-running managers, while Canaccord Genuity and Citizens Capital Markets are acting as lead managers. Completion of the offering is subject to market conditions and other customary closing conditions.